Silanes

What Silanes does

Laboratorios Silanes, S.A. de C.V. is a privately held Mexican pharmaceutical company founded in 1943, headquartered in Mexico City with a manufacturing plant in the Toluca Industrial Park and a European subsidiary in Spain. The company develops, manufactures, and commercializes a diversified portfolio of more than 50 branded pharmaceutical products across cardiometabolic (hypertension, diabetes, dyslipidemia), central nervous system, analgesic, respiratory, dermatological, nutraceutical, and anti-infective therapeutic areas, serving 3 million-plus patients in 15 countries. Through its wholly-owned Bioclon Institute subsidiary, Silanes is a world leader in antivenom research, development, and production, and operates the first National Toxicology Network for envenomation treatment in Mexico.

Silanes' underlying technology base includes a molecular biology laboratory implementing recombinant protein development for antivenom and diagnostics manufacturing, a generics product line (captopril, carbamazepine, enalapril, lysine clonixinate, and others), and a biotechnological product line based on therapeutic antibodies and peptides targeting ocular, inflammatory, neurodegenerative, autoimmune, infectious, and metabolic diseases. The company holds 150+ patents throughout its history (11 national and 99 foreign patents granted and in force, plus pending applications) and 611 registered trademarks, and reinvests approximately 10% of annual sales into new product development. R&D is complemented by genomics research partnerships with public and private health organizations focused on disease-risk markers unique to the Mexican population.

The business model combines direct B2B sales of branded generics and innovative prescription products to pharmacies, hospitals, and healthcare providers in Mexico with multi-country out-licensing of the innovative portfolio to international pharmaceutical partners in Europe, Asia, Latin America, and Africa, generating licensing royalties. The company also distributes third-party brands in Mexico (e.g., Janssen's Invokana/Invokana Duo) under in-licensing arrangements, and operates a physician-engagement ecosystem via the 'Nunca más sin ellos' mobile app, MedPoint treatment tool, and MedClass online medical education platform. Go-to-market is sales-led, supplemented by channel partnerships and direct institutional supply, primarily to the Mexican market as the core revenue base.

Name

Silanes

Legal name

Laboratorios Silanes, S.A. de C.V.

Website

https://silanes.com.mx

Company type

Private

Founded year

1943

Operating status

Operating

Headcount range

251–500 employees

Short description

Laboratorios Silanes is a privately held Mexican pharmaceutical company founded in 1943 that develops, manufactures, and commercializes 50-plus branded prescription generics, biotechnological products, and world-leading antivenoms across 15 countries, serving 3 million-plus patients.

Ownership category

akta.pro rank

Product category

Branded Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industry

Drug Product Fill-Finish & Aseptic Manufacturing Services (HLAAAKAB)

Keywords

• Branded generic pharmaceuticals
• Antivenom manufacturing
• Cardiometabolic medications
• Biotechnological therapies
• Pharmaceutical manufacturing

Headquarters

HQ city

Colonia Reforma Social

HQ country

Mexico

HQ region

Latin America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Sale of branded generic and innovative pharmaceutical products across therapeutic areas including cardiometabolic, CNS, analgesic, respiratory, and nutraceuticals. Products are sold through prescription channels to healthcare providers and pharmacies.
2. Biotechnological Products: Sale of biotechnological products based on antibodies and therapeutic peptides for ocular, inflammatory, neurodegenerative, autoimmune diseases, infectious diseases and diabetes.
3. Antivenom Products: World-leading production and sale of antivenoms that neutralize venom from stings and bites of poisonous animals, sold to healthcare institutions.
4. Diagnostic Products: Sale of diagnostic products including VIH-Instantest for HIV antibody detection and Chagas disease diagnostic tests.
5. Licensing Royalties: Revenue from out-licensing agreements granting commercialization rights to international partners for their innovative portfolio and pipeline in markets including Europe, Asia, Latin America, and Africa.
6. In-licensing Products: Products acquired through in-licensing agreements for innovative drugs in CNS, diabetes, and respiratory therapy, distributed in Mexico.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

Laboratorios Silanes is a Mexican pharmaceutical company that develops, manufactures, and commercializes branded generic and innovative pharmaceutical products across multiple therapeutic areas including cardiometabolic (hypertension, diabetes, dyslipidemia), central nervous system, analgesic, respiratory, and antivenoms. The company also produces biotechnological products based on antibodies and therapeutic peptides, diagnostic tests, and operates digital health platforms for healthcare professionals. Products are sold in 15 countries with manufacturing operations in Mexico.

Product overview

Laboratorios Silanes is a Mexican pharmaceutical company founded in 1943, offering a diversified portfolio of more than 50 branded pharmaceutical products across multiple therapeutic areas. The product portfolio is organized into several categories: (1) a Core Cardiometabolic portfolio including hypertension treatments (Bicartial, Bicartial-CTD, Captral, Lodarta), diabetes medications (Predial, Predial Plus, Glimetal, Glimetal Lex, Sil-Norboral, Glinorboral Compuesto), and dyslipidemia drugs (Trezete, Vaxtifen); (2) third-party distributed brands including Invokana and Invokana Duo (from Janssen); (3) a CNS and analgesic portfolio including Dorsal, Lobuxal, Dolo-Tiaminal, Tiaminal, Tiaminal B12 variants, Velian, Velian-B, and Malival Compuesto; (4) a world-leading antivenom portfolio produced by the Bioclon Silanes biotechnology institute; (5) diagnostic products including VIH-Instantest (HIV test) and Chagas disease test; (6) dermatological products (Sebryl, Acheflan); (7) nutraceuticals (Folivital, Limagal); and (8) respiratory and anti-infective products (Vertisal, Dotbal-S, Etral-TR). The company also operates two digital health platforms: the 'Nunca más sin ellos' app (at silanespro.com.mx) providing exclusive offers and tools for healthcare professionals, MedPoint (medpoint.com.mx) for comprehensive treatment management, and MedClass (medclass.com.mx) for online medical education. R&D activities are supported by a molecular biology laboratory developing recombinant proteins for antivenom and diagnostics, molecular diagnosis initiatives for genomics, and proteomics research. The product line spans Generics (captopril, carbamazepine, enalapril, etc.) and Biotechnological products (antibody and therapeutic peptide-based treatments for ocular, inflammatory, neurodegenerative, autoimmune, infectious diseases, and diabetes).

Differentiator

Problem solved

Functional benefit

Brands

• Bioclon Silanes: Biotechnology institute producing exclusive antivenoms globally
• Nunca más sin ellos
• Nunca más sin ellos App
• MedPoint
• MedClass

Products and services

• Cardiometabolic Portfolio Product portfolio focused on the control and treatment of arterial hypertension and dyslipidemia, contributing to the reduction of cardiovascular disease mortality. Includes branded generics such as Bicartial, Captral, Lodarta, Predial, Glimetal, Trezete, and Vaxtifen sold to healthcare providers.
• Central Nervous System Portfolio Product line for the central nervous system addressing bodily, motor, and cognitive functions, including products like Sentax (citicoline) and Lobuxal (pregabalin/tramadol). Sold to healthcare providers and pharmacies.
• Analgesic Portfolio Medication portfolio focused on relieving pain of different intensities, available through the Analgesic Speed (Velocidad Analgésica) initiative. Includes products like Dolo-Tiaminal, Velian, Etral-TR, and Dorsal.
• Respiratory Portfolio Innovative next-generation portfolio for the diagnosis and treatment of adult and pediatric patients with respiratory diseases, addressing fever, pain, and inflammation. Sold to healthcare providers.
• Nutraceuticals Portfolio Innovative vitamin product line complementing dietary needs of patients, supporting physicians in prescribing comprehensive treatments. Includes products like Folivital and Limagal.
• Antivenom Products (Bioclon Silanes) World-leading antivenoms produced by the Bioclon Silanes biotechnology institute, neutralizing venom from stings and bites of poisonous animals. Produced at the Parque Industrial Toluca manufacturing plant and sold to healthcare institutions globally.
• Diagnostic Products Rapid diagnostic tests including VIH-Instantest for HIV antibody detection and Chagas Disease Diagnostic Test for detection of antibodies against Trypanosoma cruzi. Sold to healthcare institutions and laboratories.
• Generics Line Quality generic pharmaceutical alternatives covering captopril, carbamazepine, lysine clonixinate, enalapril, and other prescription medications. Provides affordable quality alternatives to healthcare providers and patients.
• Biotechnological Line Products based on therapeutic antibodies and peptides targeting ocular, inflammatory, neurodegenerative, autoimmune disorders, infectious diseases, and diabetes. Developed using recombinant protein techniques in Silanes' molecular biology laboratory.
• Never Again Without Them (Nunca más sin ellos) App Mobile application exclusively for healthcare professionals to access offers, initiatives, and integral treatment tools, supporting better patient care in conjunction with Silanes pharmaceutical products.
• MedPoint Auxiliary digital tool for healthcare professionals to provide comprehensive treatments beyond medication, supporting integral patient care with Silanes products.
• MedClass Online learning platform offering video lessons from leading physicians from Mexico and worldwide, accessible for continued medical education by healthcare professionals.

Quantifiable outcome

• 3 million+ patients treated with Silanes medications
• +3 more outcomes

Named customers3 records

Segments8 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Bioclon InstitutecoreStrategic or Co-development PartnerJoint creation of the first National Toxicology Network of centers specialized in control and treatment of envenomation caused by venomous animals. Bioclon Silanes biotechnology institute produces exclusive antivenoms globally.
• Public Health OrganizationscoreStrategic or Co-development PartnerCollaboration agreements with public health organizations for genomics research focusing on identification of genes unique to Mexican population to predict risk of diseases such as diabetes, hypertension, and obesity.
• Private Health OrganizationscoreStrategic or Co-development PartnerPartnership with private health sector for molecular diagnosis and genomics research collaborations.
• International Pharmaceutical CompaniescoreChannel Partner/ Reseller/ DistributorLong-term partnerships with leading pharmaceutical companies worldwide under licensing and distribution agreements. Out-licensing of innovative portfolio to markets including Europe, Asia, Latin America, and Africa.
• Strategic Partners (Spain)minorStrategic or Co-development PartnerEuropean subsidiary in Spain accesses financing for developments with strategic partners in other countries.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Regional players

• Eurofarma Laboratórios: Brazilian pharmaceutical manufacturer with broad branded generics and innovative product portfolio serving Latin America. Comparable to Silanes as a Latin American peer of similar scale, serving overlapping disease burden and healthcare system dynamics.
• Aspen Pharmacare: South African-headquartered specialty and branded generic pharmaceutical company with global emerging-market reach. Comparable to Silanes in its focus on branded generics in emerging markets and its licensing-led international expansion model.

Direct peers

• Laboratorios Liomont: Mexican pharmaceutical company focused on prescription and OTC branded generics with strong domestic distribution. Comparable to Silanes in scale, therapeutic breadth and Mexican commercial footprint.
• Genomma Lab Internacional: Mexico-based, publicly listed pharmaceutical company with branded generics and OTC products sold across Latin America. Comparable in therapeutic breadth and Latin American distribution strategy, though more consumer/OTC weighted.
• Laboratorios Pisa: One of Mexico's largest domestic pharmaceutical manufacturers, offering branded generics and innovative products across multiple therapeutic areas. Closely comparable to Silanes in business model, Mexican market focus, and broad multi-therapeutic portfolio.

Emerging players

• Morepharma: Mexican specialty pharmaceutical company focused on women's health, cardiometabolic and specialty therapeutic areas. Comparable to Silanes as a Mexican peer with branded specialty pharma positioning, though smaller and more niche-focused.
• Bharat Serums and Vaccines: Indian biopharmaceutical company producing antivenoms, plasma-derived products and specialty biologics. Comparable to Silanes in the antivenom production niche and emerging-market pharmaceutical distribution model.

Broad incumbents

• Sandoz (Novartis): Global leader in generic and biosimilar pharmaceuticals spun out of Novartis. Comparable to Silanes in generic finished dosage form manufacturing across therapeutic areas, though at significantly larger scale and with broader geographic presence.
• Teva Pharmaceutical Industries: World's largest generic medicines manufacturer with broad therapeutic coverage and global distribution. Comparable to Silanes in generic finished dosage form manufacturing and out-licensing posture, though operating at vastly greater scale and geographic breadth.
• CSL Limited: Australian global biotechnology company that produces antivenoms and plasma-derived therapies. The closest large-scale comparable to Silanes/Bioclon in the antivenom niche, though CSL operates across a far broader plasma-derived biologics portfolio.

Market position

Strengths1 record

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/laboratorios-silanes

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Silanes